an article on money morning. Key take outs:
Previous trials have indicated strong results for NNZ-2591, and principal investors Milford Asset Management are hopeful about its success.‘We put the likelihood of FDA approval at 90%–95%,’ remarked portfolio manager Will Curtayne.
The expanded licensing deal with Acadia is a major win for Neuren. It gives the company a partner with a strong track record in commercialising neurological drugs. This will help Neuren to bring its other medicines to the market and generate global revenue.The deal is also a positive sign for patients with Rett syndrome and other neurological disorders. It means that they will have access to more treatment options in the future as it now has the working capital to continue its trials.
With the clear success of Daybue under its belt, investors can look ahead to further breakthroughs by the young company as it continues to grow in the biotechnology sector.The future looks brighter for the company and global Rett syndrome patients.
https://www.moneymorning.com.au/20230714/acadia-expands-neuren-asxneu-licensing-deal-shares-soar.html
Neuren Media and Analyst Coverage, page-355
-
- There are more pages in this discussion • 997 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$13.76 |
Change
0.150(1.10%) |
Mkt cap ! $1.758B | |||
| Open | High | Low | Value | Volume |
| $13.60 | $14.00 | $13.51 | $5.043M | 365.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3816 | $13.73 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $13.78 | 2834 | 1 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |